Full Report

After the Boom

Pernod Ricard is the world's second-largest spirits group — a €10.96bn portfolio of premium brands (Absolut, Jameson, Martell, Chivas Regal, Ballantine's) assembled by acquisition and run on premiumisation and pricing. A post-pandemic boom carried sales to a FY2023 record; organic sales have since fallen for two straight years as the United States and China reset at once. The shares trade near €64, roughly two-thirds below their 2021 peak. This chapter orients a reader to the business and sets the question the report exists to answer.

The company: a premium portfolio built by acquisition

Pernod Ricard was created in 1975 from the merger of two French pastis houses — Pernod (founded 1805) and Ricard (1932) — and has spent five decades buying its way to global scale [1]. The defining deals built the shelf a reader would recognise today: Irish Distillers (Jameson) in 1988, Allied Domecq (Ballantine's, Beefeater, Mumm, Perrier-Jouët) in 2005, the Seagram brands (Martell cognac, Chivas Regal, Royal Salute, The Glenlivet) in 2001, and Vin and Sprit (Absolut vodka) in 2008 [2]. The company describes itself as "the world's leading international premium spirits company" [3]; by revenue it sits second behind Diageo. In FY2025 (year ended 30 June 2025) it turned over €10.96bn with about 18,224 employees [4].

The model is straightforward to state and hard to run: own aspirational brands with legal or geographic scarcity (cognac from Cognac, champagne from Champagne, aged Scotch), sell them through mostly in-house distribution across roughly 160 markets, and lift price and mix faster than volume over time. That premiumisation is what has historically turned a low-single-digit volume business into mid-single-digit revenue growth and steady margin expansion.

How it makes money

Revenue is spread deliberately across three regions and between mature and emerging markets. In FY2025 the split was Asia / Rest of World 42%, Americas 29% and Europe 29%; emerging markets were roughly 45% of sales and mature markets 55% [5].

Source: FY2025 Sales and Results, Net Sales Analysis by Period and Region [6].

The economics are genuinely premium. Gross margin runs near 59% and the reported operating margin was 26.9% of net sales in FY2025; the company held its recurring operating margin roughly flat despite falling volumes, expanding it 64 basis points organically through cost discipline [7]. Marketing investment is deliberately heavy — around 16% of sales — because the brands, not the liquid, are the asset [8]. Cognac and prestige spirits also tie up capital for years: the group carries long-dated maturing inventories that must be laid down long before they can be sold, which is both a moat and a source of inflexibility when demand turns.

Source: FY2025 Universal Registration Document, Key takeaways [9].

The boom, and the reset

The last six years hold the whole story. The pandemic first knocked sales to €8.45bn in FY2020, then a reopening surge in on-trade and travel demand, restocking, and aggressive pricing drove net sales to a record €12.14bn in FY2023. That peak has since unwound: FY2024 fell to €11.60bn and FY2025 to €10.96bn, a reported decline of 5.5% and an organic decline of 3.0% [10].

Sources: FY2025 Sales and Results [11]; prior-year Sales and Results press releases, as reported.

Two engines cooled at the same time, which is what makes this reset unusual. In the United States — the group's single largest profit pool — distributors that had over-ordered during the boom began working inventory back down, so shipments fell faster than consumption. In China, a weak post-COVID consumer recovery hit Martell cognac, and the market was further disrupted by Chinese anti-dumping measures on European brandy that suspended normal cognac sales into travel retail. The H1 FY2026 result, reported in February 2026, showed the pressure had not passed: organic sales fell 5.9%, with the USA down 15% and China down 28%, even as India grew 4% [12].

Management's own framing is that FY2026 is "a transition year," with a Q1 decline from US destocking, soft China demand, India excise changes in Maharashtra, and cognac sales into China duty free resuming only from Q2 [13]. For the medium term (FY2027–FY2029) it guides to organic net sales growth of "+3% to +6%" per year, supported by a €1bn efficiency programme [14]. That range is itself a signal: it sits below the +4% to +7% ambition the group carried into the boom [15], so even management's recovery case embeds a lower cruising speed than the one investors paid for.

What the market has paid

The reset has been punishing for shareholders. The stock closed near €63.9 in early July 2026, down about 29% over one year and roughly 66% over five, against an all-time high above €200 reached in 2021. The market capitalisation is around €16bn. On trailing earnings the shares trade near 11 times, and the dividend — held flat at €4.70 — yields about 7.4%, a level the market usually reserves for businesses it expects to shrink [16].

Source: market data as of 3 July 2026 (Euronext Paris close); dividend per FY2025 Universal Registration Document [17].

A 7%-plus yield on a company that still earns a 27% operating margin and converts to over €1bn of free cash is not a normal pairing. It says the market has stopped treating Pernod Ricard as a reliable compounder and started pricing in the possibility that the last two years are the new baseline rather than a dip. The counter-fact a bull would raise: the same shares changed hands above €200 as recently as 2021 on a portfolio that is largely unchanged, and the sell-side one-year target still sits near €87 — so the disagreement is about durability, not about the assets.

The question this report answers

The central question this report exists to answer: whether the sales decline that began after Pernod Ricard's FY2023 peak is a cyclical trough — an inventory-and-demand reset its premium portfolio, pricing power and emerging-market growth will carry it through — or a structural downshift in spirits demand that has permanently lowered the group's growth and returns; and which of the two the depressed share price is discounting.

Everything that follows tests one side of that question or the other: the durability of the brands and pricing power, the quality of the cash and the balance sheet behind a 3.3x leverage ratio, what the US and China resets actually reveal about end demand, whether India and travel retail can carry the next leg of growth, and what has to be true for an 11x multiple and a 7% yield to be a mispricing rather than a warning.

---

Cash and the Dividend

Pernod Ricard's free cash flow no longer covers its dividend. In FY2025 the group generated €1,133m of reported free cash flow and paid €1,201m in dividends; the payout is covered only against the "recurring" free-cash-flow figure the company reports (€1,348m) [1]. Leverage has since risen to 3.8x net-debt/EBITDA — the product of falling profit, not new borrowing [2]. The balance sheet is not fragile, but deleveraging now depends on the recovery the group is still waiting for.

Sources: net-debt/EBITDA, H1 FY2026 Sales and Results [3]; free cash flow, dividend and DPS, FY2025 URD §5.3 [4].

The coverage gap

The dividend has crossed above free cash flow, and the crossover is not new. Between FY2022 and FY2025 the annual cash cost of the dividend rose from €826m to roughly €1.2bn, while free cash flow fell from a FY2022 peak toward €1.1bn. The two lines met in FY2024 and have stayed close since.

Source: derived from reported financials, FY2022–FY2025; FY2024–FY2025 figures reconcile to the FY2025 URD net-debt table (reported FCF €963m and €1,133m; dividends €1,208m and €1,201m) [5].

The company's own reconciliation is the clearest way to see it. In FY2025, self-financing capacity before interest and tax was €3,101m; a €470m increase in working capital, €844m of interest and tax, and €655m of net capital spending reduced that to €1,133m of free cash flow [6]. Dividends paid were €1,201m [7]. The gap is small — about €68m — but it is a gap, and FY2024 was wider: €963m of free cash flow against €1,208m of dividends and a further €334m of share buybacks [8]. Over the two years, reported free cash flow of about €2.1bn funded roughly €2.4bn of dividends; the €0.3bn difference, plus buybacks, came from the balance sheet.

Coverage reappears only under the company's "recurring free cash flow" measure — €1,175m in FY2024 and €1,348m in FY2025 — which restates reported free cash flow for items management classifies as non-recurring [9]. That add-back is worth naming plainly. It was €212m in FY2024 and €215m in FY2025 [10], and it repeated at €94m and €113m in the two most recent half-years [11]. A cash cost of roughly €210m a year that recurs every year — largely restructuring and strategic one-offs [12] — sits uneasily under a "non-recurring" label, especially while the €1bn efficiency programme runs to FY2029. The dividend is covered by the cash flow the company asks you to normalise, not by the cash it actually generated.

Leverage is rising on the denominator

Net debt itself has been broadly stable. On the group's definition — gross debt including lease liabilities, less cash — it moved from €10,273m at June 2023 to €10,951m at June 2024, then back to €10,727m at June 2025, helped in the latest year by a €282m foreign-exchange translation benefit that did more than the €59m of underlying debt reduction [13]. By December 2025 it stood at €11,168m, a seasonal half-year build driven by the timing of the dividend [14].

Sources: FY2025 URD §5.3 (June 2023–June 2025) [15]; H1 FY2026 Change in Net Debt (December 2025) [16].

The leverage ratio tells a different story, because the denominator is shrinking. Net-debt/EBITDA rose from 3.3x at June 2025 to 3.8x at December 2025; the company's own bridge attributes 0.4x of the increase to lower EBITDA and cash generation and 0.1x to group structure and foreign exchange — none of it to fresh borrowing [17]. Set against the 2.6x the group carried in FY2021, before the boom, the trajectory is the mirror image of the sales story in After the Boom: as profit fell, the same debt became heavier [18]. This is why the ratio, not the debt, is the number to watch: a recovery in EBITDA would pull it down without a euro of repayment, and a prolonged trough would push it higher without a euro of new debt.

What keeps this from being a solvency question

Three things separate elevated leverage from real balance-sheet stress, and all three hold here.

First, the maturity wall is a ladder, not a cliff. The bond stack runs in roughly €1–1.8bn annual tranches out to 2050, with the nearest maturities a €600m note due May 2026 and a $600m note due June 2026 — together close to the €1.1bn of cash on the balance sheet [19].

Second, liquidity is ample and the debt is covenant-light. At June 2025 the group held €1,829m of cash plus €2,810m of confirmed, undrawn revolving credit facilities [20]. The bonds carry no financial-leverage covenants — no net-debt/EBITDA test that a downgrade or a weak year could trip [21].

Third, the assets behind the debt are real and slow-moving. Inventory stood at €8.4bn at June 2025 on the reported balance sheet, a large part of it maturing Scotch, cognac and other aged spirits that gain value as they age [22]. That stock is the working-capital drag — €470m in FY2025 [23] and €610m in the latest half-year [24] — but it is also a reservoir of cash that unwinds if the group lets inventory run down toward demand.

The genuine cost is quieter: interest. Net financing has climbed as low-coupon bonds issued in the 2019–2021 era mature and are refinanced at coupons of 3.25%–3.75% [25]; in FY2025 the cost of net financial debt included €313m of bond expense and €26m of commercial-paper cost [26], and reported interest expense has roughly doubled since FY2022 on the group's income statements. Each refinancing at today's rates takes another bite out of the free cash flow that already fails to cover the dividend.

The dividend decision, and what would change the read

Management has held the dividend at €4.70 per share, unchanged year-on-year and paid in two €2.35 instalments [27]. The stated policy is a payout of "circa 50% of net profit from recurring operations" [28]. With recurring profit falling — group share of net profit fell 18% in the first half of FY2026 and earnings per share fell 20% [29] — a frozen dividend means the effective payout ratio has drifted above the policy. At roughly €64 a share, the €4.70 payout is a yield near 7.4%, a level that usually signals the market doubts the distribution will hold.

The read here is that the dividend is defensible but no longer self-funding, and that the two-sided thesis from After the Boom resolves through this line more than any other. The deleveraging plan management describes — strategic capital spending normalising from its peak, working capital releasing, growth returning — is the cyclical case stated in cash-flow terms [30]. If it delivers, EBITDA recovers, the ratio falls back toward 3x on its own, and the €4.70 is comfortably re-covered by reported cash. If the downshift is structural, the recovery in the denominator does not come, the working-capital release is smaller, and a dividend that already exceeds reported free cash flow keeps leverage elevated — at which point the group faces the choice it has so far avoided between the payout and the balance sheet.

The strongest fact against the cautious read is that none of this is stress: covenant-light debt, €4.6bn of liquidity, and an inventory asset that converts to cash on demand give management years, not quarters, to be right about the cycle. What would change the read, in order of signal value: reported free cash flow returning durably above the ~€1.2bn dividend cost; the working-capital drag turning to a release; net-debt/EBITDA turning back down from 3.8x on its own second-half seasonality; and the "non-recurring" free-cash-flow add-back shrinking rather than repeating near €210m. The first of those to appear in a results statement is the one to trust.

---

Pricing Power

Pernod Ricard's moat shows up where it should: gross margin held near 60% through a two-year sales decline, evidence that the group is not cutting shelf prices to defend volume [1]. What has broken is the premiumisation engine that drove the boom: group price/mix swung from +9% in FY2023 to negative in FY2025 [2]. Whether that reversal is discounting or geographic mix is the hinge of the EBITDA recovery the cash case (Cash and the Dividend) assumes.

The engine that drove the boom

Premiumisation is not a slogan here; it is an industry trend the group has ridden for a decade. Premium-and-above spirits have grown roughly 6.8% a year for ten years, and 8.5% a year in the super-premium tier — faster than the category as a whole [3]. Pernod's model is to price its brands into that mix and let the average bottle carry more value each year; management calls maximising pricing power "a priority in our premiumisation strategy" [4].

FY2023 was the proof. Organic price/mix reached +9%, of which +8% was pure pricing, and the group still grew volume +1% [5]. Raising list prices by high single digits without shedding volume is the signature of genuine pricing power. It carried the recurring operating margin to a record 28.3% that year [6].

Source: FY2023 Sales & Results, highlights [7].

Where the gross margin held

Through the reset that followed, the product-level moat did what a moat should: it held. Gross margin was 60.5% in FY2022, 59.7% in FY2023, 60.1% in FY2024 and 59.5% in FY2025 — a band roughly one point wide across a period in which net sales fell from their peak [8]. A company discounting to keep volume on the shelf would show that stress in gross margin first. Pernod does not.

Source: FY2025 Sales & Results, Profit from Recurring Operations bridge [9]; FY2022 URD [10].

The compression the reset did cause sits one line lower. Recurring operating margin fell from 28.3% to 26.9% — about 140 basis points — because advertising and structure costs did not fall as fast as sales [11]. That is operating deleverage on lower volume, not a lost pricing battle. The distinction matters: deleverage reverses if volume returns; a broken price line does not.

The price/mix reversal

The part of the moat that did break is the growth algorithm. On the Strategic International Brands — the thirteen names that carry roughly half the group's volume — price/mix contribution ran +4pts in FY2021, +3pts in FY2022 and a remarkable +11pts in FY2023, then decelerated to +2pts in FY2024 and turned to −5pts in FY2025 [12]. The premiumisation flywheel — more value per bottle, every year — stopped and reversed.

Source: Pernod Ricard Sales & Results releases FY2020–FY2025, Strategic International Brands tables [13]; [14].

A negative price/mix number is the fact both a bull and a bear point to. It carries two very different meanings, and separating them is the whole question.

Discounting or mix

The bull reading is that the negative number is mix, not price — the arithmetic of a changing geographic and portfolio blend rather than lower prices on the same bottle. Three pieces of evidence support it. First, gross margin held near 60%, which a genuine round of discounting would not allow [15]. Second, the group's highest-price-per-case brand collapsed: Martell cognac fell −20% in FY2025, and China — where that cognac is sold at premium prices — was down 21% on weak consumer sentiment [16] [17]. When the priciest bottles fall fastest, the average bottle gets cheaper even if no single price is cut. Third, management frames the whole episode as "the normalisation of the spirits market" after the inflation-era surge, not as a loss of brand pricing power [18].

The bear reading is that the moat is genuinely thinning, and there is evidence for that too. In H1 FY2025 the group attributed a softer gross margin partly to increased promotions alongside adverse mix — promotional spending is discounting by another name [19]. And by H1 FY2026 the negative price/mix was broad, not confined to cognac and China: Absolut −3pts, Jameson −5pts, Ballantine's −5pts, Martell −9pts [20]. Same-brand negative price/mix across the core portfolio is harder to wave off as geography.

Source: H1 FY2026 Sales & Results, Strategic International Brands table [21].

The gross margin the moat had protected finally moved in H1 FY2026, falling from 61.1% to 59.3% [22]. But the composition matters: the company attributes roughly a third of the organic decline to new US and China tariffs — a policy cost bolted onto the cost line, not a demand verdict — with the price-and-mix effect itself a smaller piece and the rest weaker fixed-cost absorption on low volume [23]. Tariffs are real and may persist, but they are a different risk from consumers refusing the price.

The read

The weight of the evidence is that Pernod's list-price power is intact and its premiumisation growth rate is impaired. The gross margin is the tell: three years of near-60% gross margin through a falling top line is not the fingerprint of a brand losing its ability to charge [24]. What the group has lost, for now, is the annual +3-to-+11-point price/mix tailwind that made the boom, dragged down by the collapse of its highest-value pockets — Chinese cognac above all — and layered with a genuine step-up in promotional intensity across the core brands.

The strongest fact against this read is that same-brand price/mix went negative across Absolut, Jameson and Ballantine's in H1 FY2026 — weakness that geography alone does not explain, and a signal that some real discounting has entered the core [25]. What would change the read: sustained gross-margin erosion below the ~59% floor for reasons other than tariffs, or price/mix that stays negative once China cognac and the US destock lap out of the comparison. Those two lines — group gross margin ex-tariffs, and Strategic International Brands price/mix — are where the cyclical-versus-structural question will actually be settled.

---

Destock or Demand

The United States is Pernod Ricard's largest market and the biggest single swing factor in whether profit recovers. Its reported sales have fallen for three straight years, but the decline is mostly a distributor destock rather than a demand collapse: shipments have run below consumer sell-out throughout, and the US spirits market has stayed in slight growth. A milder demand normalisation sits underneath — enough to temper the cyclical read, not to overturn it.

The market that moves the numbers

The US is the group's single largest market, at roughly a fifth of net sales — about €2.1bn in FY2025, weighted at 19% and falling to 17% of the group by H1 FY2026 as it shrank faster than the rest [1] [2]. Because it carries that weight, the swing in US organic net sales has driven a large share of the group's move from its FY2023 peak.

That swing is stark. Reported US organic net sales went from roughly flat at the FY2023 peak to a run of falls that deepened, not healed, over three years: −9% in FY2024, −6% in FY2025, and −15% in the first half of FY2026 [3] [4] [5].

Source: FY2023 value at c.0% per the FY2023 Sales & Results deck [6]; FY2024 US shipments down 9% per the FY2024 call [7]; FY2025 −6% [8]; H1 FY2026 −15% [9].

A three-year worsening looks, at first read, like structural decay. How to price that trajectory depends on what those shipment numbers actually measure: spirits leaving Pernod Ricard's warehouses for its distributors, not spirits leaving the shelf for the consumer.

Shipments below the shelf

Three flows move in sequence: Pernod Ricard ships to its distributors (net sales); distributors deplete stock to retailers (depletions); retailers sell out to consumers (sell-out). When the pipeline is being drained, each flow up the chain is less negative than the one below it, because inventory is being run down at every level. That is exactly the pattern in the US.

FY2024 is the one year the company disclosed all three layers at once. Shipments fell 9%; Pernod Ricard's depletions fell 7%; its sell-out fell 4%; and the spirits market's own sell-out stayed in positive territory [10]. Management said as much directly: "the shipments will likely be below the sellout" as distributor inventory came down [11].

Source: FY2024 earnings call — US shipments −9%, Pernod Ricard depletions −7%, sell-out −4%, with the overall spirits market sell-out positive [12].

The gap between the bottom of the chain and the top is the destock. Consumers pulled ~4% less Pernod Ricard product off the shelf, yet the company shipped 9% less into the trade — the difference is inventory that distributors and retailers chose not to hold, against a backdrop of high US interest rates that make carrying stock expensive [13]. The same wedge shows up in every period the company has quantified it.

Sources: FY2023 deck [14]; FY2024 call [15]; Q1 FY2025 (first-quarter FY2025 print) [16]; FY2025 results release [17]; H1 FY2026 US −15% [18].

Down the shipment column the business looks in retreat; across in the sell-out column it looks like a warehouse being emptied while the shelf holds up. In the FY2025 release the company put the same point in its own words: "USA −6%, Spirits market (inc. RTD) in slight growth… Narrowing gap-to-market through sharp execution" [19]. Shipments below the shelf, with the company slowly closing the distance to a market that is still growing.

The consumer underneath

None of this proves the US consumer is unchanged. The evidence for a genuine, if milder, normalisation is real and worth stating plainly.

The category is soft, not booming. Pernod Ricard describes the US spirits market as in "slight growth," held back by "subdued consumer confidence and economic moderation" [20]. Its own structural data shows US alcohol penetration steady at about 53% of legal-drinking-age adults across a decade, but with the moderation concentrated in frequency — consumers drinking on fewer occasions rather than quitting [21]. A stable base with falling frequency is not a demand cliff, but it is a lower cruising speed for the category than the post-Covid boom.

And Pernod Ricard is not simply riding the market. Its own sell-out has been roughly flat-to-slightly-negative even as the market grew slightly — a gap-to-market it has been narrowing, but a gap all the same [22]. The pricing side of this reset, covered in Pricing Power, shows the same softening reaching the shelf: within-brand price/mix turned negative across the core US portfolio, and promotions increased. That is demand-side pressure, not just a pipeline effect — the consumer is trading occasions and responding to price, even if not disappearing.

Why the pipeline keeps draining

The awkward fact for a clean destock story is duration. A one-off inventory correction should be measured in quarters; this one has run three years and, in H1 FY2026, got worse rather than better. Three forces explain the extension.

First, distribution itself was disrupted. Over the past year Pernod Ricard "reset our route to market" in the US and made "targeted, capability-driven distributor adjustments," against an industry backdrop of distributor "expansion, consolidation and RNDC market changes" [23]. Reassigning brands across wholesalers drains and refills pipelines on its own, on top of the cyclical destock. Second, new US tariffs on spirits arrived as a fresh cost and a reason for the trade to manage inventory tightly. Third, high interest rates keep the carrying cost of stock elevated, so distributors hold less of it structurally.

The recovery timing has slipped with each telling. In August 2024 management expected a return to US growth in FY2025 and "a return to volume growth in most markets in the second half" [24]; instead FY2025 fell 6% and H1 FY2026 fell 15%. The FY2026 guidance again leans on a destock explanation — "distributor inventory adjustment in the US, continued soft consumer demand" — with the improvement pushed into the second half [25].

The mechanical implication cuts the other way, though. Shipments cannot stay below sell-out forever: once distributor inventories reach their new, lower steady state, shipments must converge back up to consumer demand. If US sell-out is roughly flat and shipments are down 15%, the catch-up when destocking ends is a tailwind of similar order — the volume mirror image of the operating-leverage argument in Cash and the Dividend, where a recovery in EBITDA is what pulls leverage back down.

Reading the split

On the weight of evidence, the US decline is cyclical-dominant: a multi-year pipeline destock, amplified by tariffs and a route-to-market reset, layered over a real but mild demand normalisation. Shipments falling three times faster than the consumer left the shelf is the signature of inventory, not of a broken market, and the still-growing category and narrowing gap-to-market support that read.

The strongest fact against it is duration and slippage. A destock that has run three years and keeps being pushed out starts to look like the trade's judgement that steady-state demand is structurally lower, and Pernod Ricard's own sell-out is only flat rather than growing — so the "catch-up" rebound depends on category sell-out holding up. What would change the read is straightforward to monitor: US category sell-out turning clearly and durably negative would move this from destock to demand; conversely, the shipment-to-sell-out gap closing as distributor inventories normalise would confirm the cyclical case and mark the point at which US net sales stop being a drag on group profit.

---

Capital Allocation

Pernod Ricard deployed capital pro-cyclically. In FY2023, at the top of the cycle, it spent roughly €1.9bn on acquisitions and buybacks combined and pushed strategic investment toward a €1.2bn peak; as sales, margins and the share price then fell, it cut buybacks to near-zero and turned to selling assets. The policy behaved exactly as written — buybacks rank last — and the current disposals are disciplined pruning. But the timing means shareholders funded the top and are watching management tidy up at the bottom.

The stated order

Management publishes an explicit priority ladder, unchanged through the cycle: first, organic investment in strategic inventories and capital expenditure; second, value-creating acquisitions; third, a dividend at about half of recurring net profit; and only fourth, "Share buyback, when above priorities are fulfilled" [1]. Buybacks are the residual, the last claim on cash. That ordering matters for what follows: it means the buyback line is designed to swell when cash is abundant and to vanish when it is not — which is close to the opposite of buying value.

Deployment at the peak

The two boom years put that residual to work. In FY2022 the group spent about €750m on buybacks and roughly €723m on acquisitions [2]. FY2023 was heavier still: another ~€750m of buybacks and €1,129m of net acquisitions — "the most active year in a decade, with over €1bn invested to complement our portfolio," in management's words [3] [4]. The acquisitions were concentrated in exactly the pockets that later reset: US Premium-plus and agave — Código 1530 tequila, Skrewball flavoured whiskey, the Canadian ready-to-drink leader Ace Beverage, and a reinforced stake in Sovereign Brands.

Source: net acquisitions of financial assets and treasury-share cash lines, FY2023 results [5] and FY2025 results [6]. Negative values denote net inflows from disposals.

Sources: FY2023 results, cash flow statement [7]; FY2025 results, cash flow and highlights [8] [9].

Strategic investment — capital expenditure plus the aged spirit laid down for future years — is a slower lever and the least discretionary of the three, but it too peaked with the cycle. Management put "€1.2bn in Capex and Strategic Inventories" in FY2024 and has been walking it back since, guiding FY2026 strategic investment to below €900m [10]. The whisky and cognac laid down at peak prices will age into a market that is, for now, softer than the one it was ordered for.

The reversal

Once cash tightened, the residual did what a residual does. Buybacks fell from ~€750m a year to €334m in FY2024, then €11m in FY2025, and €10m in the first half of FY2026 [11] — effectively switched off, even as the shares fell by roughly two-thirds over five years. The acquisition line reversed sign: net acquisitions of €723m and €1,129m in FY2022–FY2023 became net inflows of €38m and €134m in FY2024–FY2025 as disposals overtook purchases [12]. The company that was the market's most active buyer in FY2023 had, two years on, become a net seller. The pause is consistent with the leverage picture set out in Cash and the Dividend — at 3.8x net debt to EBITDA, halting buybacks is prudent, not a blunder — but it is also the mechanical outcome of a policy that spends when the price is high and stops when it is low.

The bolt-ons that soured

Two of the boom-era purchases have already been written down in part. The wine assets acquired and held through the cycle drove a €495m impairment in FY2024 (partly offset by a reversal on Kahlúa) [13], and the first half of FY2026 carried a further €186m of goodwill and asset impairment [14]. Set against that, the balance-sheet damage has been contained: group goodwill rose from €6,145m (FY2022) to roughly €6,800m as the deals closed, then edged down to €6,406m by June 2025 — a modest net movement, not a wholesale re-rating of the acquired brands [15]. The impairments so far are the visible edge of a portfolio bought late in the cycle, not evidence that the core franchise value has cracked.

Pruning in the trough

The reversal is not only forced restraint; part of it is genuine housekeeping. Through FY2024–FY2026 the group has sold its Australian, Spanish and New Zealand wine business, then the Imperial Blue mass-market Indian whisky division to Tilaknagar Industries in November 2025, and signed to sell its US sparkling wine brands — Mumm Napa, Mumm Sparkling California and DVX — to Trinchero [16]. The stated logic is coherent with the pricing story in Pricing Power: shed the lower-margin, local and wine assets to "focus its resources on its international premium spirits and champagne brands" [17]. And these were not distress sales: the group booked net gains on disposals of €292m in FY2024 and €93m in FY2025 [18], and a further €310m gain in the first half of FY2026 [19] — proceeds above carrying value, which argues the pruning is disciplined rather than desperate.

Sources: FY2022–FY2023 results and FY2023 URD [20] [21] [22]; H1 FY2026 interim report [23].

The read

On the evidence, capital allocation over this cycle rates as competent stewardship undermined by timing. The franchise itself was built by a generation of large, value-creating deals — the acquisitive DNA traced in After the Boom — and today's portfolio surgery is the same instinct applied sensibly: sell the low-margin tail at a gain, concentrate on premium international spirits, protect the investment-grade rating. The strongest fact against a harsher verdict is that the disposals cleared their carrying value and goodwill has barely moved, so the boom-era brand book has not, so far, proved a mirage.

The strongest fact for a harsher verdict is the shape of the deployment curve. The group put its largest discretionary cash to work — roughly €1.9bn of acquisitions and buybacks in FY2023 alone — at the peak of earnings and the peak of its own share price, then withdrew both as the price collapsed. A buyback that is the residual claim on cash will always do this; it is a feature of the stated policy, not an accident of one year. Two things would change the read. If buybacks resume in scale once leverage falls back toward 3x, executed at prices far below the FY2023 levels, the pro-cyclical criticism softens into "bought high once, then bought low." If instead goodwill impairments accelerate on the Premium-plus bolt-ons as the US agave and flavoured segments stay soft, the FY2024–FY2026 write-downs stop looking like an edge and start looking like a trend.

---

Valuation

At €63.88 the shares trade on about 8.8 times trailing recurring earnings and yield 7.4% on a flat dividend — a level global premium-spirits leaders almost never reach [1] [2]. The de-rating is real and double-sourced: both the multiple and the earnings base fell. On the arithmetic, the price sits close to the structural-stagnation end of the report's central question, with the recovery the company guides to largely unpriced.

Where the shares trade

Source: closing price €63.88 (3 Jul 2026) and consensus per market data; dividend €4.70 and share count per FY2025 Sales and Results [3].

The building blocks are straightforward. About 252 million shares at €63.88 give a market capitalisation near €16.1bn; adding net debt of €11,168m at 31 December 2025 lifts enterprise value to roughly €27.3bn [4]. Against FY2025 recurring diluted earnings of €7.26 that is 8.8 times trailing profit; against the €5.77 the street expects for FY2026 it is 11.1 times, the higher figure reflecting a further guided decline rather than a richer price [5].

Source: derived from FY2025 recurring earnings [6], recurring profit €2,951m [7], net debt [8] and dividend [9]; market cap and yields at the 3 Jul 2026 price.

Two of these deserve a caveat. The forward multiple looks the most expensive of the set only because FY2026 is the trough the company itself flags — a "transition year" carrying tariffs and a further profit step-down. On the earnings the group has already banked, the shares are nearer 9 times. And the free-cash-flow yield straddles the dividend: reported FCF covers roughly 95% of the payout, the recurring figure a little over 100% (Cash and the Dividend).

A double de-rating

The stock is down about 29% over one year and roughly 66% over five, and the decline has two independent engines. The multiple compressed — a premium-spirits franchise that once cleared 20 times earnings now trades below 11 — and the earnings base fell underneath it. Recurring diluted EPS has gone from €7.90 in FY2024 to €7.26 in FY2025, with consensus at €5.77 for FY2026 before a shallow recovery to €5.88 in FY2027 [10]. A shareholder lost on both: less profit, and a lower price for each euro of it.

Sources: FY2024 and FY2025 recurring diluted EPS per FY2025 Sales and Results [11]; FY2026e and FY2027e are consensus estimates.

The de-rating is not Pernod's alone — it has swept the scale players in the category. On dividend yield, the two largest diversified spirits houses now sit at the top of the peer table: Pernod at 7.4% and Diageo at 6.4%, both far above the 2–3% these names historically paid. The premium-and-single-category peers have de-rated less — Brown-Forman yields 3.6%, Rémy Cointreau 1.9%, Campari 1.5%. The market has re-priced the diversified, mature-market-heavy model more harshly than the focused one, which is consistent with the demand and mix problems the report has already traced (Destock or Demand, Pricing Power).

Source: Pernod dividend €4.70 per FY2025 Sales and Results [12]; peer yields per market data, mid-2026.

From yield to implied growth

A 7.4% yield on a dividend the board has held flat is worth translating into a growth expectation. On a constant-growth frame with an 8–9% cost of equity — a fair range for a stable consumer-staples franchise — a starting yield of 7.4% is consistent with roughly 1% long-run growth in the payout. That is well below the +3% to +6% organic net-sales growth the company guides to for FY2027–FY2029 [13]. The gap between the two is the substance of the valuation: at €63.88 the price embeds something close to stagnation, not the recovery management describes.

That framing carries its own qualifier. The same low-single-digit implied growth is what makes the yield fragile rather than generous — a genuinely structural downshift would pressure the very payout that anchors the price, since reported free cash flow already covers the dividend only marginally (Cash and the Dividend). A 7.4% yield is a floor only for as long as the dividend holds.

The range and the two scenarios

The report's central question — whether the post-FY2023 decline is a cyclical trough or a structural downshift — maps cleanly onto price. The two readings imply very different earnings paths, and the sell-side's own target range spans both.

Source: derived from consensus recurring EPS and FY2023–FY2025 reported recurring earnings [14]; scenario multiples are illustrative.

The arithmetic is deliberately simple, and it lands close to where analysts actually sit. The consensus mean target of about €87 is roughly FY2024-level recurring earnings at today's multiple — a partial-recovery bet with no re-rating required. The street high near €122 needs both: earnings back toward the FY2023 peak and a multiple closer to a normal staples 14 times. And the street low, at €62.5, is essentially the current price — the structural view, in which the FY2026 trough is the new base. That the low target and the market price coincide is the clearest sign that the price is discounting the pessimistic reading.

Source: 12-month price targets and current price per consensus market data (19 analysts), as of 3 Jul 2026.

The dispersion itself is informative. With a low of €62.5 and a high of €122, the sell-side has an unusually wide spread — a near-doubling between the most and least optimistic — which is what genuine disagreement over cyclical-versus-structural looks like in a target table. The balance of opinion is cautious rather than bullish: eight buy ratings against ten holds and one sell, and estimate revisions have run against the stock, with the large majority of FY2027 EPS changes in the past month cut rather than raised.

My read, offered once: at roughly 9 times the earnings it has already banked and a 7.4% yield, the price is discounting close to the structural end of the through-line — little of the guided recovery is in the number, which is where the asymmetry sits if the decline proves cyclical. The strongest fact against treating that as an opportunity is that estimates are still falling and the dividend underpinning the yield is only thinly covered, so a structural downshift would erode the floor rather than pay you to wait.

What would change the read

The price is a coiled version of the same debate the rest of the report has run, so the same evidence moves it. A turn up in US category sell-out that ends the distributor destock (Destock or Demand), a resolution of the China cognac and EU-brandy duties that restores Martell's earnings, EPS revisions that stop falling, or deleveraging back below 3x net-debt/EBITDA — any of these would pull the implied path away from stagnation. Absent them, the 8.8-times multiple and the 7.4% yield are the market's price for a business it currently expects to hold, not to grow.

---

India and Cognac

Pernod Ricard's recovery case rests on two concrete pillars rather than a general rebound. India — 13% of sales and now the group's second-largest market — has grown organically every year through the downturn [1]. Martell's collapse is largely one country: cognac fell 17% in the latest half but rose 20% outside China, where a duty-free suspension tied to an EU-brandy anti-dumping case did most of the damage [2]. Both pillars are where the cyclical reading, if correct, should appear first.

Sources: H1 FY26 Results Presentation, Top Markets [3] and brand performance [4]. India organic +4% is +8% excluding the divested Imperial Blue.

The one market still growing

In the half to December 2025, India was the only major market in organic growth: net sales rose 4% (8% excluding the divested Imperial Blue value brand), against declines of 15% in the US, 28% in China, 12% across the Americas and 3% in Europe [5] [6].

Source: H1 FY26 Results Presentation, Top Markets [7] and Regions [8].

This is not a one-half accident. India grew 13% in FY2023 [9], 6% in FY2024 [10] and 6% again in FY2025 — 8% excluding Imperial Blue [11]. Somewhere in FY2024 it passed the US to become the group's second-largest market by net sales [12].

Source: FY23, FY24 and FY25 results presentations and H1 FY26 presentation [13] [14] [15] [16]. FY2025 and H1 FY26 are +8% excluding Imperial Blue.

The support underneath the number is structural. India is the world's largest whisky market, adds roughly 25 million new legal-drinking-age adults a year, and sits in the early stages of premiumisation [17]. Pernod Ricard holds the number-one position, with local powerbrands (Royal Stag, Blenders Pride) beneath imported labels — Jameson is now the number-one imported spirit in the market, and the new premium-local Xclamat!on range extends the ladder upward [18]. At roughly €1.4bn of net sales, India is now a scaled compounder rather than a frontier bet.

Two caveats keep this from being a clean offset. First, size: at 13% of the group, India cannot by itself absorb a US (17%) and China (7%) that together are a quarter of sales and falling faster — the mid-term plan needs the mature markets to stop shrinking, not just India to keep growing [19]. Second, the reported number understates a currency drag: the rupee fell about 13% against the euro in the half, cutting €87m from reported net sales, so India's organic strength converts into a softer euro line [20]. Near term, Maharashtra excise changes are also a headwind, weighted to the first quarter [21]. Working the other way, the group expects import-tariff relief from 2026 as trade agreements take effect, with India named among the sources of that easing [22].

Martell, cognac and the China duty-free reset

The other pillar is a resolving event more than a durable engine. Martell — the group's cognac house — fell 17% organically in the latest half, but grew 20% excluding China [23]. Almost the entire decline is one country and one channel.

Source: H1 FY26 Results Presentation, brand performance [24].

The mechanism matters because it is specific and dated. In December 2024, China technically suspended the duty-free regime on cognac as part of its anti-dumping investigation into EU brandy [25]. That suspension fell hardest on the China travel-retail channel — Global Travel Retail sales dropped 13% in FY2025 — and left distributors holding inventory into year-end [26] [27]. Management framed the resolution as a minimum-price undertaking on cognac closing out the anti-dumping case, alongside a separate import-duty increase from 5% to 10% that costs around €45m a year [28].

That resolution arrived. In July 2025 China's commerce ministry issued its final ruling — average anti-dumping duties of about 32% on EU brandy — but accepted price undertakings from 34 producers, including Martell, that exempt them from the duties provided they sell above agreed minimum prices. Martell duty-free sales into China resumed in the second quarter of FY2026, and Travel Retail rebounded to a 3% decline for the half, with the group guiding it to be broadly stable across FY2026 [29] [30]. The mechanical piece of the cognac drag is therefore reversing on a known timetable.

The demand piece is less certain, and it is the counter-fact a bull has to hold in view. The duty-free normalisation restores a channel; it does not restore Chinese consumer appetite for cognac, which management describes as pressured by a tightened regulatory environment on high-end on-trade and weak consumer sentiment [31]. Martell's own price/mix was still negative 9% in the half — the premium ladder is compressing, not just the volume shipped [32]. And external trade data through late 2025 showed EU brandy imports into China still failing to recover after the case closed — evidence that the undertaking removed a barrier without turning the underlying market. On the wider tariff exposure, management's planning scenario runs to roughly €200m of annualised tariff cost, of which it expects to offset about half through supply-chain and pricing actions [33].

What the recovery requires

Set against the medium-term plan, the two pillars carry different weight. The group's own illustration of reaching the top of its +3% to +6% mid-term range leans on India above +6%, the US back above +3%, Travel Retail around +3%, and China no longer a drag [34]. India is the durable compounder in that build; cognac and Travel Retail are a cyclical snap-back off a suppressed base; and the largest single swing remains the US shipment-to-sell-out catch-up examined in Destock or Demand.

The honest read is that these pillars support the cyclical interpretation without settling it. India shows the premiumisation thesis alive and scaling in the one large market where it was never in doubt, and the cognac reset is a discrete, resolving event rather than permanent demand loss — both cut toward "cyclical". But India is too small to offset the mature-market declines on its own, and Chinese cognac demand, distinct from the duty mechanics, has not yet turned. What would move the read is straightforward to watch: India organic growth holding above the mid-single digits once the Imperial Blue base effect washes out, Travel Retail returning to growth as guided, and Martell's China volumes rebuilding rather than merely the channel reopening.

---

Cyclical or Structural

This chapter puts the report's six pillars on one grid and maps the answer to price. The evidence is genuinely two-sided: an inventory-led, two-market reset that reverses mechanically, set against a US correction now in its third year and discounting that has spread into core brands. The balance tilts cyclical, with a structurally lower ceiling — and at roughly €64 the shares already sit near the structural end, so the asymmetry rewards patience more than prediction.

The two readings on one grid

Every pillar of this report answers the same question two ways. The table below is the report's shared-fact ledger: each row is a number that is not in dispute, read once as a cyclical trough and once as a structural downshift, with the evidence that would settle it. The spine of the report (After the Boom) framed the question; this is where the pieces line up against each other.

Sources: US shipment-vs-sell-out and India per H1 FY26 presentation [1] and the half-year press release [2]; gross margin per FY2025 results [3]; Martell per H1 FY26 presentation [4]; leverage per H1 FY26 results [5]; cash and dividend per FY2025 URD [6].

Two features of the grid matter more than any single row. First, the cyclical and structural readings share the same facts — no row turns on a disputed number, only on interpretation, which is why the debate has stayed unresolved for two years. Second, the deciding evidence in the right-hand column is, in almost every case, a series that will print in a future results statement rather than a judgement to be made now. The report's earlier chapters traced how each line got to where it is; the synthesis is that they will resolve together, and largely on the volume signal that Destock or Demand isolated.

The lever the cyclical case leans on is time, not cash

The cyclical case rests on the balance sheet buying management years to be right (Cash and the Dividend). It is worth sizing what that cushion actually is, because the €8.4bn inventory is often cited as a cash reservoir. It is mostly not releasable.

Source: H1 FY2026 balance sheet, inventory breakdown at 31 December 2025 — aged work-in-progress is €7,077m of the €8,371m total [7].

Of the €8,371m of inventory at December 2025, €7,077m is aged work-in-progress — Scotch and cognac laid down years ahead of sale and committed to future vintages [8]. Running it down releases cash only by starving the premium supply the whole thesis depends on. Just €1,181m is finished-goods and other stock, and it fell only about €60m over the half [9]. The cushion that funds the dividend through the trough is therefore liquidity and covenant-light debt, not an inventory unlock — which is to say it buys time, at a rising cost of debt, rather than a quick reduction in leverage. That narrows the cyclical case: it can be patient, but it cannot self-fund a fast deleveraging.

Three scenarios, mapped to price

The question resolves cleanly onto price because the two readings imply different earnings paths on a multiple that has already compressed below 11x. The framework below reuses the arithmetic from Valuation: a recurring-earnings estimate for each reading, a plausible multiple, and the resulting share price — which lands, in each case, close to where a segment of the sell-side already sits.

Source: derived from FY2024–FY2025 reported recurring EPS [10] and consensus estimates; scenario multiples are illustrative.

Source: current price €63.88 (3 Jul 2026) and derived scenario values; recurring EPS base per FY2025 results [11].

The arithmetic is deliberately plain, and it lands where analysts already are. The structural bar sits on top of the current price: at ~€64 the market is paying for the FY2026 trough as if it were the new base, which is the same conclusion the street's low target of €62.5 reaches. Partial recovery — the consensus mean near €87 — needs earnings back toward the FY2024 level on today's multiple, no re-rating required. The high case needs both: earnings toward the FY2023 peak and a multiple back to a normal staples 14x. That the low target and the market price coincide is the clearest read on what the price discounts: the pessimistic case, with the company's own +3% to +6% medium-term guide [12] largely unpriced.

What would settle it

The scenarios do not need to be predicted; they can be watched. Each row below is a line item, where it will appear, and the threshold that would move the read from one column of the grid to the other. None requires access management does not already report.

Sources: US, Travel Retail and price/mix per H1 FY26 results and presentation [13] [14]; gross margin [15]; leverage [16]; FCF and dividend [17].

Of these, the US sell-out line carries the most signal. The report's cyclical case is built on shipments having fallen far faster than the consumer left the shelf (Destock or Demand); were Pernod Ricard's own US sell-out to turn durably negative rather than hold roughly flat, the destock story would convert into a demand story, and several of the other rows — price/mix, gross margin, the FCF gap — would likely follow it into the structural column.

Where the balance sits

The report's central question — whether the decline that began after FY2023 is a cyclical trough or a structural downshift — does not resolve to a single verdict, and the honest synthesis is a tilt, not a call. Most of the fall is inventory and two-market channel effects that mechanically reverse: US shipments running 15 points below a roughly flat consumer, a Martell drag that is one country and one suspended channel, a leverage ratio that rose purely because profit fell. Against that, three facts keep the structural reading alive and cannot be waved away: the US correction has run three years and deepened rather than healed, discounting has spread from adverse geographic mix into the core brands' own price/mix, and even management's recovery guides only to +3% to +6% — a lower cruising speed than the business investors paid for at the peak. Capital allocation offers no tie-breaker either way: the record is disciplined but pro-cyclical (Capital Allocation), so the recovery cash, when it comes, has to be deployed better than the last surplus was.

The evidence, on balance, favours the cyclical read with a structurally lower ceiling — and the reason to hold that view calmly rather than firmly is the price itself. At ~€64 the market has already marked the shares to the structural end of its own range, so a partial recovery toward consensus is upside the price is not demanding, while the structural case is close to fully discounted. The fact that most threatens the read is the destock's duration; the signal that would settle it first is US sell-out. Both will show up in the results statements to come, which is where this report ends and the monitoring begins.

---

Family Control

Pernod Ricard is a founder-family-controlled company. Société Paul Ricard, wholly owned by the Ricard family, holds 14.29% of the capital but 20.64% of the votes through France's double-voting rule, and has lifted its stake in every year of the downturn [1]. With Groupe Bruxelles Lambert alongside it, two long-term anchors hold roughly a third of the votes. This shapes two things a buyer of the stock inherits: who the dividend really answers to, and whether a takeover can ever happen.

Sources: shareholding at 30 June 2025, FY2025 URD Ch.9 [1]; board independence, FY2025 URD §2.1.2.1 [2].

Who owns it, and who runs it

The Group carries the founding family's name because the family still controls it. Société Paul Ricard — a holding company wholly owned by the Ricard family — held 36,042,689 shares at 30 June 2025, or 14.29% of the capital, and its four related vehicles (Le Garlaban and the three Delos Invest companies) are controlled by it under French law [1]. Because long-held registered shares carry double votes (see below), that 14.29% of capital converts into 20.64% of the votes — a 1.44-to-1 wedge between economic exposure and voting power [1].

The family also runs it. Alexandre Ricard, a grandson of founder Paul Ricard, has been the Group's combined Chairman and CEO since 11 February 2015 [3]. Two further family members sit on the board — César Giron, another grandson of the founder, and Patricia Ricard Giron — both as non-independent directors [2]. The second anchor is Groupe Bruxelles Lambert, the Belgian holding company, which has held its stake since 2017 — 6.82% of capital and 11.36% of the votes — and is represented on the board by Ian Gallienne [1]. Together the two hold 21.11% of the capital and 32.00% of the votes. The rest of the register is a wide institutional free float — MFS, BlackRock and Wellington each held between 3% and 5% at year-end, none of them a control bloc [1].

Source: FY2025 URD, breakdown of share capital and voting rights over the last three years [1].

The family's grip is tightening, not loosening. Through the very years the share price fell, Société Paul Ricard's holding rose from 14.07% of capital (20.41% of votes) at June 2023 to 14.21% (20.57%) at June 2024 to 14.29% (20.64%) at June 2025 [1]. Some of that drift comes mechanically — the Group cancels the shares it buys back, so a static family holding rises as a percentage of a shrinking count — but the share count held also rose each year, from 35.96m to 36.04m [1]. The people closest to the business added to it while the market sold.

The control machinery

France gives long-term owners tools that a common-stock reading of "14% of capital" misses, and Pernod Ricard uses all of them. Three matter.

Double voting rights. Any fully paid share registered in the same name for at least ten years carries two votes, a right the Group has run since 1986 [4]. It rewards exactly the behaviour the family and GBL exhibit — hold, in registered form, for a long time — and it is why their 21% of capital speaks with 32% of the voice. A short-term holder gets one vote; the anchors get two.

A 30% voting cap. No single shareholder may cast more than 30% of the votes at a meeting, whatever their holding [4]. This cuts both ways: it stops the family from ever holding an outright majority of votes on its own, but it is also a classic anti-takeover device — a hostile acquirer who bought a majority of the shares would still be capped at 30% of the votes.

Early-warning disclosure. The bylaws require any holder crossing 0.5% of capital to notify the Company, and again at every further 0.5% up to 4.5% — a granularity far tighter than the statutory thresholds, and one that makes silent stake-building visible early [4]. Sitting behind all of it, the Group's financing agreements carry change-of-control clauses that allow lenders to demand early repayment if control shifts [5]. Taken together, the structure means Pernod Ricard is effectively not acquirable against the family's wishes. A buyer of the stock should price that certainty in — for what it protects and for what it forecloses.

What it means for the case

The ownership structure is not a governance footnote; it bears directly on the two questions this report keeps returning to — will the dividend hold, and can the Group afford to be patient through a demand reset.

On the dividend. Cash and the Dividend showed the payout has drifted above reported free cash flow and is defended only on the company's "recurring" measure. Ownership tells you who is doing the defending, and why. Société Paul Ricard is a pure holding company; its principal asset is the Pernod Ricard stake, so the Group's dividend is the family vehicle's main source of income. At the €4.70 per share held flat since FY2023, the family's 36.04m shares collect roughly €169m of dividends a year [6]. A controlling owner that lives on the dividend is structurally disinclined to cut it — and the record fits: after a COVID trim to €2.66 in FY20, the dividend was rebuilt to €4.70 by FY23 and has been held there through two years of falling profit rather than reduced to match cash generation [7]. This is the company-specific reason the 7.4% yield has more support than a coverage ratio alone implies. It is support, not a guarantee: the policy is a payout ratio, not a floor, and a deep enough or long enough trough could still force a cut — but the controlling shareholder's incentives lean hard the other way.

Source: dividend history FY19–FY23, FY2023 URD [7]; €4.70 held for FY24–FY25, FY2025 URD [6].

On patience. A long-horizon, family-and-GBL controlled register lets management prioritise the things that only pay off over years — brand equity, and the aged Scotch and cognac that sit maturing on the balance sheet — over the quarterly earnings a widely-held peer must protect. For a company whose central question is whether it can wait out a multi-year reset, a patient owner is an asset. It is the same feature that lets the Group hold the dividend and the aged-inventory strategy at the same time.

The counter. Entrenchment cuts both ways, and the same structure that supports the income case caps the upside. There will be no takeover premium and no activist lever: the 30% cap, double votes and change-of-control clauses foreclose the external pressure that forces value out of an unloved, cash-generative asset elsewhere. If the market is wrong about Pernod Ricard, the correction has to come from the business recovering, not from a bid — a depressed price can simply persist. Governance concentration adds to the caution. The combined Chairman-and-CEO role puts strategy and its oversight in one family member's hands; it is mitigated by a 58.3% independent board and a Lead Independent Director in post since 2019 [8], but it is the same combined authority under which the pro-cyclical, peak-of-cycle acquisitions flagged in Capital Allocation were made. The structure that will defend the dividend is also the structure that owns the timing mistakes.

The net read: for an income-oriented buyer, family control is a support — it aligns the largest voter with the payout and the long horizon the recovery thesis needs. For a buyer hoping the market's discount gets closed by an outside catalyst, it is a wall. Value here will be realised through the P&L or not at all.